|
Medical Advocates Enfuvirtide [T-20] (Fuzeon) |
|
|
|
|
|
Last updated:
August 26, 2008
Perinatal Journal Data are in the Perinatal Data Page. Pediatric Journal Data are in the Pediatric Data Page |
|
|
| General Reports |
|
|
|
| Pharmacokinetics |
The safety, plasma pharmacokinetics, and antiviral activity of subcutaneous
enfuvirtide (T-20), |
|
|
| Drug/Drug Interactions |
Lack of Enzyme-Inducing Effect of Rifampicin on the Pharmacokinetics of
Enfuvirtide. |
|
|
| Viral Dynamics |
gp41 First Heptad Repeat Involves Distinct Regions of gp41 and Is Consistently Modulated by gp120 Interactions with the Coreceptor. Derdeyn CA, Decker JM, Sfakianos JN, et al. . J Virol 2001 Sep;75(18):8605-8614 Abstract Activation of the formyl peptide receptor by the HIV-derived peptide T-20 suppresses interleukin-12 p70 production by humanmonocytes. Braun MC, Wang JM, Lahey E, Rabin RL, Kelsall BL. Blood 2001 Jun 1;97(11):3531-3536 Abstract
Strong in vitro synergy between the fusion inhibitor T-20 and the CXCR4
blocker AMD-3100 J Acquir Immune Defic Syndr 2000 Oct 1;25(2):99-102 Abstract |
|
|
| Adverse Events |
Injection site reactions with the HIV-1 fusion inhibitor enfuvirtide. |
|
|
| Resistance |
|